Howell D A, Wang H I, Roman E, Smith A G, Patmore R, Johnson M J, Garry A, Howard M
Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK.
Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Hull, UK.
BMJ Support Palliat Care. 2017 Jun;7(2):150-157. doi: 10.1136/bmjspcare-2014-000793. Epub 2015 Jul 8.
Home is considered the preferred place of death for many, but patients with haematological malignancies (leukaemias, lymphomas and myeloma) die in hospital more often than those with other cancers and the reasons for this are not wholly understood. We examined preferred and actual place of death among people with these diseases.
The study is embedded within an established population-based cohort of patients with haematological malignancies. All patients diagnosed at two of the largest hospitals in the study area between May 2005 and April 2008 with acute myeloid leukaemia, diffuse large B-cell lymphoma or myeloma, who died before May 2010 were included. Data were obtained from medical records and routine linkage to national death records.
323 deceased patients were included. A total of 142 (44%) had discussed their preferred place of death; 45.8% wanted to die at home, 28.2% in hospital, 16.9% in a hospice, 5.6% in a nursing home and 3.5% were undecided; 63.4% of these died in their preferred place. Compared to patients with evidence of a discussion, those without were twice as likely to have died within a month of diagnosis (14.8% vs 29.8%). Overall, 240 patients died in hospital; those without a discussion were significantly more likely to die in hospital than those who had (p≤0.0001). Of those dying in hospital, 90% and 75.8% received haematology clinical input in the 30 and 7 days before death, respectively, and 40.8% died in haematology areas.
Many patients discussed their preferred place of death, but a substantial proportion did not and hospital deaths were common in this latter group. There is scope to improve practice, particularly among those dying soon after diagnosis. We found evidence that some people opted to die in hospital; the extent to which this compares with other cancers is of interest.
对许多人来说,家被视为理想的死亡地点,但血液系统恶性肿瘤(白血病、淋巴瘤和骨髓瘤)患者在医院死亡的频率高于其他癌症患者,其原因尚未完全明确。我们研究了这些疾病患者的理想死亡地点和实际死亡地点。
本研究纳入了一个既定的基于人群的血液系统恶性肿瘤患者队列。纳入了2005年5月至2008年4月期间在研究区域内两家最大医院被诊断为急性髓系白血病、弥漫性大B细胞淋巴瘤或骨髓瘤且于2010年5月前死亡的所有患者。数据来自医疗记录以及与国家死亡记录的常规关联。
纳入了323例死亡患者。共有142例(44%)讨论过理想死亡地点;45.8%希望在家中死亡,28.2%希望在医院死亡,16.9%希望在临终关怀机构死亡,5.6%希望在养老院死亡,3.5%未做决定;其中63.4%在理想地点死亡。与有讨论记录的患者相比,没有讨论记录的患者在诊断后一个月内死亡的可能性是前者的两倍(14.8%对29.8%)。总体而言,240例患者在医院死亡;没有讨论记录的患者在医院死亡的可能性显著高于有讨论记录的患者(p≤0.0001)。在医院死亡的患者中,分别有90%和75.8%在死亡前30天和7天接受了血液学临床诊疗,40.8%在血液学科室死亡。
许多患者讨论过理想死亡地点,但仍有相当比例的患者未进行讨论,后一组患者在医院死亡的情况很常见。改善医疗实践仍有空间,尤其是在诊断后不久即将死亡的患者中。我们发现有证据表明一些人选择在医院死亡;将此情况与其他癌症进行比较很有意义。